Pharmaceutical

ITM targets US approval for radiopharmaceutical after Phase III readout

The company is planning an NDA submission for the neuroendocrine tumour-targeting ITM-11 later in 2025.

Mar 7, 2025 - 06:00
ITM targets US approval for radiopharmaceutical after Phase III readout
The company is planning an NDA submission for the neuroendocrine tumour-targeting ITM-11 later in 2025.
Read the original article

Tags:

Previous Article

Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks

Next Article

Project Optimus: The evolution of dose optimisation in oncology

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Grifols gears up for FDA approval of fibrinogen replacement therapy

Grifols gears up for FDA approval of fibrinogen replace...

Feb 14, 2024

FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga continues

FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga ...

Aug 13, 2024

STAT+: FDA’s letter to medical device maker iRhythm is a warning for the industry

STAT+: FDA’s letter to medical device maker iRhythm is ...

Jun 12, 2023